Nasus remains a pure-play clinical-stage biotech with no revenue and an escalating cash burn, but the $15M February round extends runway into Q2 2027 — enough to reach NS002 pivotal data in early 2027. The go-concern warning and prior CEO departure add overhang, but the new CEO and advancing pipeline suggest a binary catalyst ahead. Monitor for IND submission (planned Q3 2026) and pivotal trial initiation (Q4 2026). The 2.7M unexercised warrants ($6.53 strike) represent overhang but could also provide an automatic capital injection if exercised upon positive data.
Price Chart
Executive Summary
Nasus Pharma reported Q2 2026 results: net loss widened to $5.9M (from $1.3M in H1 2025) as R&D spend surged 796% to $2.6M to advance lead candidate NS002 (intranasal epinephrine for anaphylaxis). Cash runway extended to ~$11.9M via a $15.0M February private placement (including 2.7M shares + warrants) and management projects funding through Q2 2027. The company also announced the appointment of industry veteran Brendan O'Grady as CEO after the prior CEO's separation.
Key Facts
- Net loss for H1 2026 was $5.9M vs $1.3M in H1 2025 — a 375% increase driven by clinical-stage R&D ramp.
- Cash and short-term deposits stood at $11.9M as of June 30, 2026, up from $4.3M at Dec 2025, following a $15.0M private placement of shares and warrants in February.
- R&D expenses reached $2.6M (up from $0.3M), primarily from NS002's Phase 2 development; G&A rose to $3.4M (from $0.5M) due to public company costs.
- CEO Dan Teleman separated on July 22, 2026, replaced by Brendan O'Grady (effective July 27); O'Grady receives $500K base + change-in-control bonus of $750K and 210,000 options.
- NS002 pivotal study on track to start Q4 2026 with topline data expected Q1 2027; NS003 first-in-human PK study planned for Q3 2026.
- Management discloses substantial doubt about going concern — additional capital will be required beyond Q2 2027.
- Ordinary Warrants from the February private placement (2.7M shares, exercise $6.53) remain unexercised; if exercised in full, would add $17.6M in gross proceeds.
Financial Impact
Net loss grew to $5.9M for H1 2026 vs $1.3M for H1 2025, a $4.7M increase. Cash position improved to $11.9M from $4.3M, but accumulated deficit reached $24.5M.
Risk Factors
- Substantial doubt about going concern — additional funding needed post-Q2 2027.
- Pre-revenue status with no approved products and no guarantee of FDA approval for NS002 or NS003.
- Dilution risk: 2.7M outstanding warrants (exercisable at $6.53) plus 817K share options and 37.6K underwriter warrants.
- Key-person risk from CEO transition: new CEO's shareholder-approved package includes change-in-control bonus, creating potential M&A overhang.
- Clinical risk: NS002 only tested in small cohorts (12-patient pilot, 12-patient Phase 2 not powered for significance).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-038651 |
| Exhibit: ex99-3.htm | 0001493152-26-038651 |
| Exhibit: ex99-2.htm | 0001493152-26-038651 |
| Document: form6-k.htm | 0001493152-26-038651 |
| Document: 0001493152-26-038651-index-headers.html | 0001493152-26-038651 |
| Document: 0001493152-26-038651-index.html | 0001493152-26-038651 |
| Document: 0001493152-26-038651.txt | 0001493152-26-038651 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers